July 03, 2024
13 min pay attention
On this episode of Assembly Mic, we carry you pearls and views from the 2024 ASCO Annual Assembly, in addition to Healio’s high headlines from the assembly.
Andrew Hantel, MD, discusses outcomes of a research on racial disparities in acute myeloid leukemia trials. :27
Christine McMahon, MD, discusses outcomes of the part 3 ASC4FIRST research, which examined asciminib versus tyrosine kinase inhibitors for sufferers with newly recognized chronic-phase CML. 3:30
Andrew Hantel, MD, discusses researching inequities in acute myeloid leukemia therapy in traditionally marginalized communities. 4:35
Christine McMahon, MD, presents outcomes of a randomized trial of a care mannequin for sufferers with acute myeloid leukemia and myelodysplastic syndrome. 7:09
Christine McMahon, MD, highlights the ACCESS research into post-transplant graft-versus-host illness, which produced “spectacular” charges of post-transplant general survival at 1 yr. 10:22
Learn the complete protection right here:
Sources/Disclosures
Collapse
Disclosures:
Hantel stories no related monetary disclosures. McMahon stories receiving institutional funding from Syndax and Syros and serving on a security monitoring committee for Kura Oncology.
Assembly Mic: ASCO Concentrate on Leukemia
